Substance P and pain in adults with chronic plaque psoriasis across treatment groups

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center, cross-sectional observational study will measure serum Substance P levels in about 100 adults with chronic plaque psoriasis. Participants will be grouped by current treatment: IL-17 inhibitors, conventional systemic therapy (methotrexate or acitretin), or topical/no systemic therapy. Researchers will collect assessments of psoriasis severity, neuropathic pain features, central sensitization, itching, and dermatology-related quality of life, and compare results across treatment groups. The study aims to explore whether Substance P levels correlate with clinical symptoms and how they may vary with treatment approach, without testing a treatment effect. It is observational in nature and will not assign interventions beyond recording current therapies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥18 years
* Diagnosis of chronic plaque psoriasis
* Ability and willingness to provide written informed consent
* For the IL-17 inhibitor group: current treatment with an IL-17 inhibitor for at least 8 weeks
* For the conventional systemic therapy group: current treatment with methotrexate or acitretin for at least 6 weeks
* For the topical therapy/treatment-naive group: topical therapy only or no previous treatment, with no systemic therapy, biologic therapy, or phototherapy within the previous 6 months

Exclusion Criteria:

* Known diabetes mellitus, HbA1c ≥6.5%, or fasting plasma glucose ≥126 mg/dL
* Vitamin B12 level \<200 pg/mL
* Known peripheral neuropathy or peripheral neuropathy detected during neurological evaluation and/or electromyography
* Neuropathy related to uremia or thyroid disease
* Chronic renal failure or chronic liver failure
* Active infection
* Active malignancy
* Active inflammatory arthritis in patients with psoriatic arthritis
* Pregnancy or breastfeeding
* Chronic heavy alcohol use

Where it's running

• Istanbul Training and Research Hospital
  Istanbul, Istanbul, Turkey (Türkiye) Recruiting

Study contacts

• Study coordinator: Yasemin Dündar Şahin, Dermatology resident physician
• Email: yasemindundar97@gmail.com
• Phone: +905394254565

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Roflumilast 0.3% Cream for chronic plaque psoriasis and nail psoriasis

  This study tests whether applying roflumilast 0.3% cream daily for 24 weeks helps people 12 years and older with chronic plaque psoriasis and moderate-to-severe nail psoriasis.

  Recruiting Phase 4 Modern Research Associates, PLLC · Dallas, Texas · NCT07725822

• Apremilast versus methotrexate for moderate to severe plaque psoriasis

  This test compares apremilast and methotrexate to see which works better for adults (18–60) with moderate to severe plaque psoriasis who have not had systemic therapy in the past 3 months.

  Recruiting Early Phase 1 Hayat Abad Medical Complex, Peshawar · Peshawar, Khyber Pukhtunkhwa · NCT07337434

• Ponesimod in adults with moderate-to-severe chronic plaque psoriasis

  This study tests whether ponesimod is safe and helps clear moderate-to-severe plaque psoriasis in adults aged 18–65.

  Recruiting at 10 sites Phase 3 Vanda Pharmaceuticals · Glendale, Arizona and 9 other locations · NCT07362017

• How safe and well ZP9830 works in people with plaque psoriasis over 8 weeks

  This study tests whether ZP9830 is safe and tolerable in adults with plaque psoriasis for 8 weeks, with a comparison to placebo.

  Recruiting Phase 1 Zealand Pharma · Leiden, South Holland · NCT07733089

• Secukinumab retention in adults with plaque psoriasis and MASLD in Spain

  This study tests how long people with plaque psoriasis and MASLD stay on secukinumab in real-world Spain, using EMR data from several hospitals.

  Recruiting at 9 sites Novartis · Badalona, Barcelona and 8 other locations · NCT07683065

• Long-term ORKA-001 treatment for adults with plaque psoriasis

  This open-label extension will try ORKA-001 long-term in adults with moderate-to-severe plaque psoriasis who completed a previous ORKA-001 study.

  Recruiting at 39 sites Phase 2 Oruka Therapeutics, Inc. · Phoenix, Arizona and 38 other locations · NCT07449702

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.